help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on August 28, 2003
Endocrinology, doi:10.1210/en.2003-0364
A more recent version of this article appeared on December 1, 2003
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
144/12/5293    most recent
Author Manuscript (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Åkesson, L.
Right arrow Articles by Degerman, E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Åkesson, L.
Right arrow Articles by Degerman, E.

Submitted on March 25, 2003
Accepted on August 18, 2003

Dual Effects of Pituitary Adenylate Cyclase-Activating Polypeptide and Isoproterenol on Lipid Metabolism and Signaling in Primary Rat Adipocytes

Lina Åkesson1*, Bo Ahrén1, Vincent C. Manganiello1, Lena Stenson Holst1, Gudrun Edgren1, and Eva Degerman1

1 Section for Molecular Signaling, Department of Cell and Molecular Biology, Lund University, Sweden, Department of Medicine, Lund University, Sweden, Pulmonary-Critical Care Medicine Branch, NHLBI, National Institutes of Health, Bethesda, MD, USA

* To whom correspondence should be addressed. E-mail: lina.akesson{at}medkem.lu.se.

Pituitary adenylate cyclase-activating peptide (PACAP) is a neuropeptide that exerts its effects throughout the body by elevating the intracellular amounts of cAMP. In adipocytes, an increased amount of cAMP is associated with increased lipolysis. In this work we evaluated the effects of PACAP38 on triglyceride metabolism in primary rat adipocytes. Stimulation of adipocytes with PACAP (0.1-100 nM) resulted in stimulation of lipolysis to the same extent as isoproterenol. Lipolysis was blocked by 25 µM of the protein kinase A (PKA) inhibitor H-89 and potentiated in the presence of 10 µM OPC3911, a phosphodiesterase 3 (PDE3) inhibitor. In addition, PACAP38 induced activation of PKA. Insulin efficiently inhibited PACAP38-induced lipolysis in a phosphatidyl inositol 3-kinase and PDE3-dependent manner. Interestingly, we also found that PACAP38, as well as isoproterenol, induced potentiation of lipogenesis in the presence of insulin. These results show that PACAP38 and isoproterenol, mediate catabolic as well as anabolic effects in adipocytes, depending on the concentration of insulin present. We speculate that in the early postprandial state and during fasting, when insulin levels are low, PACAP and {beta} -adrenergic catecholamines induce lipolysis whereas when higher levels of insulin are present, these agents potentiate the anabolic effect of insulin, i.e. storage of triglycerides.


Key words: Lipolysis • lipogenesis • metabolism • adipose tissue • PACAP • insulin signaling • Type 2 Diabetes







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society